The role of inflammation and anti-inflammatory medication in asthma

Respiratory Medicine

Volumn 96, Issue SUPPL. 1, 2002, Pages

  Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; GLUCOCORTICOID RECEPTOR; HISTAMINE; IMMUNOGLOBULIN E; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN; SALBUTAMOL; SALMETEROL; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

AIRWAY; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; BRONCHUS MUCOSA; CELL MIGRATION; CELL TYPE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; EOSINOPHIL; EPITHELIUM CELL; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; LIPOPHILICITY; LONG TERM CARE; LUNG ALVEOLUS EPITHELIUM; LUNG ENDOTHELIUM; LUNG FIBROBLAST; LUNG FUNCTION; LUNG LAVAGE; MACROPHAGE; MAST CELL; NOCTURNAL ASTHMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYMPTOM; T LYMPHOCYTE ACTIVATION; IMMUNOLOGY; PATHOLOGY; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; ETHANOLAMINES; HUMANS; LEUKOTRIENE ANTAGONISTS; MACROPHAGES; MAST CELLS; T-LYMPHOCYTES;

EID: 0013088326     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2001.1232     Document Type: Article

References (69)

1. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1-S53.
2. Tavakkoli A, Rees PJ. Drug treatment of asthma in the 1990s. Achievements and new strategies. Drugs 1999; 57: 1-8.
3. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489.
4. National Institutes of Health: National Heart Lung and Blood Institute, Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. Bethesda, MD: National Institutes of Health (publication No. 95-3659); 1995.
5. National Institutes of Health: National Heart Lung and Blood Institute, National Asthma Education and Prevention Programme. Expert panel report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health (publication No. 97-4051); 1997.
6. British Guidelines on Asthma Management: 1995 review and position statement. Thorax 1997; 52 (Suppl 1): S1-S21.
7. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-1745.
8. Djukanovic R. Asthma: a disease of inflammation and repair. J Allergy Clin Immunol 2000; 105: S522-S526.
9. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50: 515-596.
10. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54: 825-857.
11. Rosenwasser LJ. New immunopharmacologic approaches to asthma: role of cytokine antagonism. J Allergy Clin Immunol 2000; 105: S586-S592.
12. Vrugt B, Wilson S, Underwood J et al. Mucosal inflammation in severe glucocorticoid-dependent asthma. Eur Respir J 1999; 12: 1245-1252.
13. Hamzaoui A, Hamzaoui K, Salah H, Chabbou A. Lymphocytes apoptosis in patients with acute exacerbation of asthma. Mediators Inflamm 1999; 8: 237-243.
14. Berman JS, Weller PF. Airway eosinophils and lymphocytes in asthma. Birds of a feather. Am Rev Respir Dis 1992; 145: 1246-1248.
15. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298-304.
16. Forsythe P, Ennis M. Adenosine, mast cells and asthma. Inflamm Res 1999; 48: 301-307.
17. Barnes PJ. Endogenous inhibitory mechanisms in asthma. Am J Respir Crit Care Med 2000; 161: S176-S181.
18. Tokuyama K, Lötvall JO, Barnes PJ, Fan Chung K. Inhaled formoterol inhibits histamine-induced airflow obstruction and airway microvascular leakage. Eur J Pharmacol 1991; 193: 35-39.
19. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway N Engl J Med 1999; 340: 197-206.
20. Busse W, Raphael GD, Galant S et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001; 107: 461-468.
21. Nelson HS, Busse WW, Kerwin E et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106: 1088-1095.
22. Johnson M. Pharmacology of long-acting beta-agonists. Ann Allergy Asthma Immunol 1995; 75: 177-179.
23. Lipworth BJ. Airway subsensitivity with long-acting beta-2 agonists. Drugs Saf 1997; 16: 295-308.
24. Redington AE. Rees PJ. Long-acting inhaled beta-2 agonists in the management of asthma: recent advances and current recommendations. Int J Clin Pract 1998; 52: 482-486.
25. Anderson GP. Formoterol: pharmocology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 1993; 52: 2145-2160.
26. Nightingale JA, Rogers DF, Barnes PJ. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Respir Crit Care Med 1999; 159: 1786-1790.
27. Wallin A, Sandström T, Soderberg M et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1998; 158: 79-86.
28. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152: 1170-1174.
29. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235-1239.
30. Yates DH, Kharitonov S, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta-2 agonist. Am J Respir Crit Care Med 1996; 154: 1603-1607.
31. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
32. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-1373.
33. van der Molen T, Postma DS, Turner MO et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997; 52: 535-539.
34. Pauwels RA, Löfdahl C-G, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
35. Rahman SU, Rhodes CG, Hughes JMB. Effect of corticosteroids on pulmonary beta adrenergic receptor density and function. Eur Respir J 1998; 12: 156S.
36. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996; 154: S21-S27.
37. Djukanovic R, Homeyard S, Gratziou C et al. The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. Am J Respir Crit Care Med 1997; 155: 832.
38. Haahtela T, Jarvinen M, Kava T et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331: 700-705.
39. Busse WW, Chervinsky P, Condemi J et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101: 457-463.
40. Boe J, Rosenhall L, Alton M et al. Comparison of dose-response effects of inhaled bedomethasone dipropionate and budesonide in the management of asthma. Allergy 1989; 44: 355.
41. Clissold SP, Helms PJ. Budesonide. A primary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 518.
42. Brogden RN, McTavish D. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44: 375-407
43. Osterman K, Carlholm M, Ekelund E et al. Effect of 1 year daily treatment with 400 mg budesonide (Pulmicort Turbuhaler®) in newly diagnosed asthmatics. Eur Respir J 1997; 10: 2210-2215.
44. Herjavecz I, Blomqvist P, Serrano A. Efficacy of once- and twice-daily administration of budesonide via Turbuhaler® as initial therapy in patients with mild persistent asthma. Respir Med 1999; 93: 230-235.
45. McFadden ER, Casale TB, Edwards TB et al. Administration of budesonide once daily by means of Turbuhaler® to subjects with stable asthma. J Allergy Clin Immunol 1999; 104: 46-52.
46. Kemp J, Wanderer AA, Ramsdell J et al. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 1999; 82: 463-471.
47. Jónasson G, Carlsen K-H, Sødal A, Jónasson C, Mowinckel P. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma. Eur Respir J 1999; 14: 150-154.
48. Chisholm L, Dekker FW, Knuistingh Neven A, Petri H. Once-daily budesonide in mild asthma. Respir Med 1998; 92: 421-425.
49. Möller C. Once-daily inhaled corticosteroids in children with asthma: dry powder inhalers. Drugs 1999; 58(Suppl 4): 35-41.
50. Pedersen S, Ramsgaard-Hansen O. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995; 95: 29-33.
51. Kemp JP, Skoner DP, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999; 83: 231-239.
52. Shapiro G. Once-daily inhaled corticosteroids in children with asthma-nebulisation. Drugs 1999; 58: 43-49.
53. Mellon M. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1998; 104: S191-S199.
54. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-381.
55. Shapiro G, Bronsky EA, LaForce CF et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998; 132: 976-982.
56. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343: 1064-1069.
57. Grossman J, Busse W, Kreitzer S. Double-blind, crossover trial of formoterol aerosol in patients with asthma. 1996 Annual Meeting of the American College of Allergy, Asthma and Immunology 1996; 33: Abstract No. P35.
58. Kemp JP, Chervinsky P, Nelson HS. A randomized, double-blind, placebo-control led, dose-response study with Formoterol Turbuhaler®. J Allergy Clin Immunol 1997; 99: S329.
59. de Blic J, Kuusela AL. Formoterol dry powder capsules for inhalation in children with asthma treated over one year [abstract]. Eur Respir J Suppl 1995; 19: 14.
60. Kesten S, Chapman KR, Broder I et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992; 69: 415-420.
61. Steffensen I, Faurschou P, Riska H, Rostrup J, Wegener T. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. Allergy 1995; 50: 657-663.
62. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42: 115-137
63. Tattersfield AE, Postma DS, Barnes PJ et al. Exacerbations of asthma. A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160: 594-599.
64. Kips JC, O'Connor JB, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001.
65. Wilding P, Clark M, Thompson Coon J et al. Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 1997; 314: 1441-1446.
66. Kelsen SG, Church NL, Gillman SA et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma 1999; 36: 703-715.
67. Aubier M, Pieters WR, Schlosser NJJ, Steinmetz K-O. Salmeterol/ fluticasone propionate (50/500 mg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876-884.
68. Shapiro G, Lumry W, Wolfe J et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161: 527-534.
69. Eickelberg O, Roth M, Lörx R et al. Ligand-independent activation of the glucocorticoid receptor by beta 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005-1010.